Cryo-Cell International (NYSEAMERICAN:CCEL) Price Target Lowered to $8.50 at Maxim Group

Cryo-Cell International (NYSEAMERICAN:CCEL) had its price target lowered by Maxim Group from $9.00 to $8.50 in a research note released on Tuesday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Cryo-Cell International Trading Down 1.3 %

CCEL stock opened at $7.03 on Tuesday. The stock has a market capitalization of $56.66 million, a price-to-earnings ratio of -6.63 and a beta of 0.53. Cryo-Cell International has a 1 year low of $5.35 and a 1 year high of $9.50.

Cryo-Cell International Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Friday, February 14th were given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 14.22%. The ex-dividend date of this dividend was Friday, February 14th. Cryo-Cell International’s dividend payout ratio is currently -94.34%.

Institutional Investors Weigh In On Cryo-Cell International

A number of hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its position in shares of Cryo-Cell International by 68.5% during the 3rd quarter. Geode Capital Management LLC now owns 39,860 shares of the company’s stock worth $254,000 after acquiring an additional 16,203 shares in the last quarter. Rowlandmiller & PARTNERS.ADV acquired a new stake in shares of Cryo-Cell International during the 4th quarter worth about $107,000. Northern Trust Corp raised its position in shares of Cryo-Cell International by 78.2% during the 4th quarter. Northern Trust Corp now owns 38,902 shares of the company’s stock worth $288,000 after acquiring an additional 17,066 shares in the last quarter. Topline Capital Management LLC acquired a new stake in shares of Cryo-Cell International during the 4th quarter worth about $354,000. Finally, CreativeOne Wealth LLC acquired a new stake in shares of Cryo-Cell International during the 4th quarter worth about $113,000. Institutional investors and hedge funds own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.